A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

CONCLUSION: A ChAdOx1 85A prime - MVA85A boost is well tolerated and immunogenic in healthy UK adults. PMID: 31735500 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31735500?dopt=Abstract

Source: Vaccine - November 13, 2019 Category: Allergy & Immunology Authors: Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, Sheehan S, Thomas ZM, Wright D, Stockdale L, Hamidi A, O'Shea MK, Dwivedi K, Behrens HM, Davenne T, Morton J, Vermaak S, Lawrie A, Moss P, McShane H Tags: Vaccine Source Type: research